KF 22678
Latest Information Update: 26 Oct 2006
Price :
$50 *
At a glance
- Originator Kyowa Hakko
- Class Antineoplastics; Pyrans
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Oct 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 06 Oct 1999 Preclinical development for Cancer in Japan (Unknown route)